CRITICAL PATH INSTITUTE

Arneric-et-al-2018

Biochemical Pharmacology

Review

Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments

Stephen P. Arneric[a*], Volker D. Kern[b], Diane T. Stephenson[c]

ARTICLE INFO

ABSTRACT

1. The need for data sharing and cross-concentric biomarker development